We provide support
that's customized to
your patient

We provide
support that's
customized to
your patient

go down arrowPhotographs are not of actual
patients or caregivers.

Every patient has distinct needs

Each patient is assigned a dedicated support team to help ensure the best possible experience. While the program is optional, we encourage patients to take advantage of this free service.

We can help your patients by:

  • Providing a caring support team from confirmed diagnosis through postsurgery follow-up
  • Ensuring a single point of contact to help navigate insurance coverage and connect your patients with financial assistance resources as needed
  • Helping to coordinate visits to the treatment center
  • Answering any nonmedical questions along the way

*Patient Authorization is included within the enrollment and Statement of Medical Necessity (SMN) forms and is a required step in the process. For your convenience, it is also available in Spanish as a separate document.

Necessary steps to begin your patient's treatment journey

LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physicians.

Determine if your patient has confirmed biallelic RPE65 mutation-associated retinal dystrophy
If your patient has not had a genetic test, learn more here

Your patient has confirmed biallelic RPE65 mutations, but is not connected with a treatment center

Fill out an enrollment form*

Submitting this form allows Spark® Therapeutics to enroll your patient into the program, investigate insurance, and schedule a treatment center consultation.

Schedule consultation

Your patient's support team will help schedule a consultation at a designated treatment center.

Your patient has confirmed biallelic RPE65 mutations and is already connected with a treatment center

Fill out a Statement of Medical Necessity (SMN)

If eligible, a treatment center specialist fills out an SMN for your patient. An SMN confirms eligibility to receive treatment and begins insurance benefits investigation.

Your patient's journey Once an SMN has been received, along with the patient's consent, your patient's support team will communicate the next steps

*Patient participation in Spark Therapeutics Generation Patient Services is voluntary and the decision to participate has no effect on the ability to get treatment or the nature of the treatment.

LUXTURNA (voretigene neparvovec-rzyl) is only administered at Ocular Gene Therapy Treatment Centers

Spark Therapeutics has designated select treatment centers to help ensure the quality of LUXTURNA from storing and handling to administration. Each treatment center is staffed with healthcare professionals, including retinal specialists, nurses, and genetic counselors, who have experience caring for patients with inherited retinal diseases.

The criteria for selection included:

  • Specialized scientific or clinical experience relevant to the administration of LUXTURNA
  • The ability to properly receive, store, and prepare LUXTURNA
  • Dedication to providing customized care
  • The ability to coordinate and manage patient logistics with our Spark Therapeutics Generation Patient Services team
  • A commitment to pharmacy and surgical training

You may continue to play an active role after referring your patient to a treatment center. In addition to regular appointments with your patient, you may also help with postprocedure care and answering medical questions along the way.

Ocular Gene Therapy Treatment Centers

1Bascom Palmer Eye Institute

Miami, FL 33136

View on map

2Baylor Eye Center

Houston, TX 77030

View on map

3Casey Eye Institute

Portland, OR 97239

View on map

4Children’s Hospital of Philadelphia

Philadelphia, PA 19104

View on map

5Cincinnati Children’s Hospital

Cincinnati, OH 45229

View on map

6Kellogg Eye Center, University of Michigan

Ann Arbor, MI 48105

View on map

7Massachusetts Eye and Ear

Boston, MA 02114

View on map

8Penn Medicine, Scheie Eye Institute

Philadelphia, PA 19104

View on map

9University of Iowa Hospitals and Clinics

Iowa City, IA 52242

View on map

10The Vision Center at Children’s Hospital Los Angeles

Los Angeles, CA 90027

View on map

LUXTURNA (voretigene neparvovec-rzyl) Reimbursement Guide for Treatment Centers

We have created a comprehensive guide to help you with many aspects of navigating the access and reimbursement process for your patients.

The guide provides instructions and information on:

  • Patient journey for LUXTURNA
  • Spark Therapeutics Generation Patient Services
  • Benefits investigations, prior authorizations, and appeals
  • Financial assistance programs
  • LUXTURNA distribution
  • Coding and claims

We assist your patients with travel logistics

In some cases, it will take more than a day's worth of travel to visit our treatment centers—which can be challenging to many patients. To help streamline the process, our support team will do their best to coordinate a travel itinerary that works with your patient's schedule.

Because of legal requirements, some services and resources are not available to patients with government insurance.

We have specialists who can help patients get the information and resources they need to access treatment

Navigating insurance and managing the financial aspects of treatment don’t have to be overwhelming.

Our support specialists can offer your patients assistance with navigating:

  • Commercial insurance copays and out-of-pocket costs
  • Understanding of government insurance copays and out-of-pocket costs
  • Financial assistance resources as needed

FAQs

Q:What is Spark Therapeutics Generation Patient Services? What assistance can they provide my patient?

A:Generation Patient Services is a program sponsored by Spark Therapeutics for patients who have confirmed bilallelic RPE65 gene mutations and may be candidates for treatment with LUXTURNA (voretigene neparvovec-rzyl). Our goal is to provide your patients with personalized assistance throughout the patient's journey.

The Spark Therapeutics Generation Patient Services support team will:
  • Contact your patient within 1 to 2 business days after receiving the completed enrollment form
  • Provide your patient with a caring support team, from confirmed diagnosis through postsurgery follow-up
  • Ensure a single point of contact to help your patient navigate insurance coverage and get connected with financial assistance resources as needed
  • Help to coordinate your patient’s treatment center visits
  • Answer nonmedical questions your patient may have along the way

Because of legal requirements, not all services and resources are available to patients with government insurance.

Enrollment in Spark Therapeutics Generation Services is voluntary and your patients are not required to enroll in order to receive therapy with LUXTURNA.

Q:Why do my patients need to use an Ocular Gene Therapy Treatment Center?

A:Spark® Therapeutics carefully selected treatment centers to support patient care. Each treatment center was selected based on specific criteria and is staffed with retinal specialists, nurses, and other healthcare professionals who have experience treating patients with inherited retinal diseases and have been trained in administering LUXTURNA.

The criteria for treatment center selection included:
  • Specialized scientific or clinical experience relevant to the administration of LUXTURNA
  • The ability to properly receive, store, and prepare LUXTURNA
  • Dedication to providing customized care
  • The ability to coordinate and manage patient logistics with our Spark Therapeutics Generation Patient Services team
  • A commitment to pharmacy and surgical training

Q:How is a treatment center selected for my patient?

A:If you decide that LUXTURNA is right for your patient, several factors will be considered in determining the treatment center: your patient's insurance coverage, in an effort to minimize out of pocket costs; your patient's and the treatment center's schedules; and your preference, among other considerations.

Q:Are financial assistance resources available to help with out-of-pocket expenses?

A:Yes, there are resources available to assist your patient with out-of-pocket costs. Eligibility for this support varies depending on the type of insurance your patient has. Your Spark Therapeutics Generation Patient Services support team can help determine which resources are most appropriate and help your patient get connected.

Learn about financial assistance resources in this patient and caregiver insurance guide.

Q:Will insurance cover LUXTURNA for my patient?

A:Getting insurance approval for LUXTURNA may involve several steps. With your patient’s consent, Spark Therapeutics Generation Patient Services will contact your patient’s insurance company and request information on coverage and the approval process. Once a prescribing physician at a treatment center has determined that a patient is eligible for treatment with LUXTURNA, he/she will begin the request for treatment approval, known as prior authorization. The Generation Patient Services team will be there to set expectations about the process and will inform your patient of any updates related to coverage and prior authorization along the way.

Learn about coverage options in this patient and caregiver insurance guide.

Q:How can I determine if LUXTURNA is right for my patient?

A:LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).

If your patient hasn’t had genetic testing, visit LUXTURNAHCP.com to order RPE65 genetic test kits.

Q:Does my patient need to enroll in Spark Therapeutics Generation Patient Services to obtain treatment?

A:Participation in Spark Therapeutics Generation Patient Services is voluntary and is not required to get treatment with LUXTURNA. Your patient may choose to participate in all, some, or none of the services offered. Participating or deciding not to participate in these services will have no effect on their ability to get treatment or the nature of their treatment or care. Generation Patient Services does not provide medical advice.

Q:How do I get my patient started on LUXTURNA?

A:Once a completed enrollment form has been submitted, a member of the Patient Services team will reach out to your patient and schedule a consultation at an Ocular Gene Therapy Treatment Center if he/she has confirmed biallelic RPE65 mutation-associated retinal dystrophy. A prescribing physician at the treatment center will determine if your patient has viable retinal cells and their eligibility for LUXTURNA. If it’s been determined that your patient is eligible, LUXTURNA will be ordered directly from the treatment center.

Q:Which are the treatment centers that are administering LUXTURNA?

A:See below for list of centers:

  • Bascom Palmer Eye Institute – Miami, FL
  • Baylor Eye Center – Houston, TX
  • Casey Eye Institute – Portland, OR
  • Children’s Hospital of Philadelphia - Philadelphia, PA
  • Cincinnati Children’s Hospital - Cincinnati, OH
  • Kellogg Eye Center, University of Michigan – Ann Arbor, MI
  • Massachusetts Eye and Ear – Boston, MA
  • Penn Medicine, Scheie Eye Institute - Philadelphia, PA
  • University of Iowa Hospitals and Clinics - Iowa City, IA
  • The Vision Center at Children’s Hospital - Los Angeles, CA